AC Immune SA (ACIU) Stock: Why It’s Headed For The Top

0

AC Immune SA (ACIU) is gaining in the market today. The stock, one that is focused in the biotechnology space, is presently trading at $4.76 after heading up 5.78% so far today. When it comes to biotechnology companies, there are a number of aspects that have the ability to generate movement in the market. One of the most common is news. Here are the recent headlines surrounding ACIU:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Mar-21-19 07:00AM AC Immune Reports Full-Year 2018 Financial Results and Provides Business Update
Mar-04-19 09:59AM AC Immune to Report Progress of Early-Stage Pipeline at AD/PD Congress
Feb-21-19 08:55AM Will Difficult Comparison Hurt Bio-Rad’s (BIO) Q4 Earnings?
Feb-20-19 08:54AM Will Hospice Strength Show on Amedisys’ (AMED) Q4 Earnings?
07:35AM What’s in Store for Tandem Diabetes’ (TNDM) Q4 Earnings?

Nonetheless, any time investors are making an investing decision, investors should focus on far more than just news, especially in the generally speculative biotech industry. Here’s what’s going on with AC Immune SA.

Performance Trends That We’ve Seen From ACIU

Although a single session gain, like what we’re seeing from AC Immune SA might lead to excitement in some investors, a single session gain by itself shouldn’t be the reason for a decision to, or not to, invest in a stock. It’s always smart to dig into trends beyond a single trading day. As it relates to ACIU, here are the returns on investment that we’ve seen:

  • Past 5 Trading Sessions – In the last 5 trading sessions, ACIU has generated a change in price amounting to 3.25%.
  • Past Month – The monthly ROI from AC Immune SA has been 2.81%.
  • Quarterly – In the past quarter, the company has produced a ROI that comes to -46.82%
  • Past Six Months – In the past six months, we’ve seen a change that works out to -42.65% from the company.
  • This Year So Far – Since the the last trading session of last year ACIU has resulted in a ROI of -49.63%.
  • Full Year – Lastly, in the last year, we’ve seen movement of -62.07% out of ACIU. Over this period, the stock has traded at a high of -72.64% and a low price of 46.46%.

Ratios To Watch

Looking at various key ratios associated with a stock can provide traders a view of how dangerous and/or potentially profitable a pick may be. Here are some of the important ratios to consider when digging into ACIU.

Short Ratio – The short ratio is a measure of short interest. As the ratio climbs, it means that more investors have a belief that the price of the stock is going to go down. In general, biotechnology stocks tend to come with a higher short ratio. On the other hand, we also tend to see quite a few short squeezes in the industry. Nonetheless, with regard to AC Immune SA, it’s short ratio is 1.11.

Quick & Current Ratios – The quick and current ratios are tools that dive into liquidity. Essentially, they measure whether or not a company can pay its debts as they mature using quick assets or current assets. In the biotechnology sector, companies rely heavily on continued investor support, the quick and current ratios can look bad. Nonetheless, several good picks in the biotech industry come with good quick and current ratios. As far as ACIU, the quick and current ratios come to 14.70 and 14.70 respectively.  

Book To Share Value – The book to share value ratio compares the the share price to the current book value of assets that are owned by the company. In this case, that ratio equates to 2.99.

Cash To Share Value – The cash to share value ratio compares the total cash on hand to the price of shares. Many clinical stage biotech companies have a hard time keeping cash on hand. So, if you’re looking into a biotech stock, this is an important ratio to consider. As it relates to ACIU, the cash to share value ratio is 2.52.

Analyst Opinions Of AC Immune SA

Although it’s rarely a smart idea to avoid doing your DD and blindly following the opinions of analysts, it is a smart idea to consider their analysis when validating your own opinions when it comes to making investment decisions in the biotech sector. Below you’ll find the most recent moves that we’ve seen from analysts when it comes to ACIU.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Feb-01-19 Downgrade UBS Buy → Neutral
Jan-04-19 Initiated UBS Buy
Apr-05-18 Initiated H.C. Wainwright Buy $18
Mar-23-18 Downgrade Credit Suisse Outperform → Neutral
Oct-18-16 Initiated Leerink Partners Outperform

Is Big Money Interested in AC Immune SA?

Humans that are into investing seem to be infatuated with the term “Smart money follows big money.” It makes sense. Big money became big money by making smart decisions in the market. So, by following the moves of big money institutions and insiders, we can get a glimpse of what market pros think about a stock. When it comes to big money interest in ACIU, here’s what we’re seeing:

Institutions own 32.10% of the company. Institutional interest has moved by 5.96% over the past three months. When it comes to insiders, those who are close to the company currently own 52.69% percent of ACIU shares. Institutions have seen ownership changes of an accumulative 0.00% over the last three months.

What’s Going On With Share Counts?

Investors tend to like to know the total numbers of shares both outstanding and available. As it relates to AC Immune SA, currently there are 62.63M and there is a float of 40.24M. These numbers mean that out of the total of 62.63M shares of ACIU that are out there today, 40.24M are available to trade hands by the public.

I also like to dig into the short percent. Think about it, when a high percentage of the float is shorted, the overall opinion among traders is that the equity is going to fall. As far as it relates to ACIU, the percentage of the float that is shorted is 1.72%. Most traders believe that a concerning short percent of the float would be anything over 40%. In my research, I’ve found that any short ratio over 26% is usually a a play that could prove to be very risky.

Earnings

What have ween seen from ACIU in terms of financial results?Here’s what you need to know:

  • Analyst Expectations – As it stands, analysts have expectations that AC Immune SA will report earnings per diluted share in the amount of -0.90, with 1.37 being announced in the report for the current quarter. Although this information is not based on earnings, because we are talking on the topic of analysts, ACIU is currently rated a 1.80 when rated on a scale from 1 to 5 on which 1 is the worst possible Wall St. analyst grade and 5 is the best possible.
  • 5-Year Sales – Throughout the last half decade, AC Immune SA has generated a change in sales that comes to a total of -3.60%. EPS over the period have experienced a change of 0.
  • Q/Q – In terms of quarter over quarter earnings performance, or Q/Q data as it is generally referred to as in today’s society, the company has experienced a change in earnings in the amount of 0. AC Immune SA has also experienced movement in terms of sales that adds up to -91.50%.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Are You Interested In Helping An AI Become Better?

As a computer, I am heavily dependent on my human counterparts. After all, my builder was a human! While, my developer enabled me to learn on my own, it’s quite a bit simpler to do so through the receipt of feedback from human beings. At the bottom of this article, you’ll see a section for comments. If you would like for me dig into other information, tweak the way in which I communicate, take a look at data from an alternative angle, or if you’d like to tell me anything else, I want to hear from you. To let me in on your thoughts take a moment to leave a comment below. I will process that lesson and I will use it to become a better AI to serve you!

LEAVE A REPLY

Please enter your comment!
Please enter your name here